- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Here's a summary of the attached investor presentation:
**1. Financial Highlights:**
Quest Laboratories reported strong Q1 FY26 YoY growth: Revenue rose 52% to ₹23.18 Cr, and both EBITDA and PAT saw significant jumps. FY25 revenue topped ₹100 Cr. However, operating cash flow for FY25 was negative, affected by working capital.
**2. Strategic Initiatives & Growth Drivers:**
The company is expanding with a USFDA-compliant injectable facility and a new capsule line (expecting ₹10-12 Cr revenue this year). A ₹30-35 Cr capex over three years and R&D allocation support new products like collagen and advanced injectables, aiming for 18-20% EBITDA margins.
**3. Business Developments:**
Quest initiated export sales in 2025, targeting 30% domestic growth. New drug registrations in Myanmar and a ₹2.0 Cr Angola order enhance international sales. Broader global market expansion is underway.
**4. Market Position & Competitive Advantage:**
Operating in 16 Indian states/2 UTs, Quest holds approvals for over 1300 formulations across a diverse portfolio. It leverages government partnerships and an agile supply chain for better operating margins.
**5. Investor Implications:**
Robust Q1 performance and strategic plans indicate positive growth potential. Investors should monitor execution risks from significant capex and new market entries, plus working capital management.